3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
3
Pancreatic Neoplasms
2
Gliosarcoma
2
Glioma
2
Glioblastoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lung Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Carboplatin
98
Pemetrexed
70
pembrolizumab
68
Cisplatin
59
Paclitaxel
54
Docetaxel
45
Gemcitabine
37
Erlotinib Hydrochloride
24
Nivolumab
23
osimertinib
17
Bevacizumab
17
durvalumab
14
Cetuximab
13
130-nm albumin-bound paclitaxel
13
Gefitinib
11
Etoposide
11
Drug Therapy
11
Ipilimumab
9
Injections
9
Albumin-Bound Paclitaxel
9
Vinorelbine
8
Radiotherapy
8
motexafin gadolinium
7
capmatinib
7
atezolizumab
7
epacadostat
6
Taxes
6
Cyclophosphamide
6
vandetanib
5
entinostat
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Neoplasms
×
1-methyltryptophan
×
Clear all
NCT00739609
2020-05-28
D-1MT
Lumos Pharma
Phase 1
Terminated
17 enrolled